Analysts' Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
TipRanksApr 15 07:10 ET
Supernus Pharmaceuticals Analyst Ratings
BenzingaFeb 28 10:39 ET
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
TipRanksFeb 28 07:31 ET
Supernus Pharmaceuticals (SUPN) Receives a Buy From Piper Sandler
TipRanksJan 25 07:28 ET
Supernus Pharmaceuticals (SUPN) Receives a Buy From Piper Sandler
TipRanksNov 30, 2023 06:50 ET
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $43
BenzingaNov 9, 2023 14:56 ET
Supernus Pharmaceuticals Analyst Ratings
BenzingaNov 9, 2023 14:53 ET
Promising Progress and Potential of Qelbree Bolsters Buy Rating for Supernus Pharmaceuticals
TipRanksNov 9, 2023 01:19 ET
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Lowers Price Target to $42
BenzingaOct 25, 2023 15:38 ET
Supernus Pharmaceuticals Analyst Ratings
BenzingaOct 25, 2023 15:37 ET
Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS)
TipRanksAug 21, 2023 08:20 ET
Piper Sandler Sticks to Their Buy Rating for Supernus Pharmaceuticals (SUPN)
TipRanksAug 9, 2023 07:25 ET
Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $46 From $45, Keeps Overweight Rating
MT NewswiresMay 10, 2023 10:12 ET
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46
BenzingaMay 10, 2023 09:36 ET
Analysts Offer Insights on Healthcare Companies: Supernus Pharmaceuticals (SUPN), Cue Biopharma (CUE) and Guardant Health (GH)
TipRanksMay 10, 2023 07:30 ET
Jefferies Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
TipRanksApr 10, 2023 08:16 ET
Stifel Nicolaus Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
TipRanksJan 29, 2023 21:10 ET
Piper Sandler Adjusts Supernus Pharmaceuticals Price Target to $47 From $40, Maintains Overweight Rating
MT NewswiresJan 23, 2023 08:44 ET
Supernus Pharmaceuticals Analyst Ratings
Benzinga Analyst RatingsJan 23, 2023 07:13 ET
Piper Sandler Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $47
Benzinga Real-time NewsJan 23, 2023 07:12 ET
No Data
No Data